About this trial
Low-grade glioma (LGG) represent typically slowly growing primary brain tumors with world health organization (WHO) grade I or II who affect young adults around their fourth decade. Radiological feature on MRI is a predominantly T2 hyperintense signal, LGG show typically no contrast uptake. Radiotherapy plays an important role in the treatment of LGG. However, not least because of the good prognosis with long term survivorship the timing of radiotherapy has been discussed controversially. In order to avoid long term sequelae such as neurocognitive impairment, malignant transformation or secondary neoplasms initiation was often postponed as long as possible
Eligibility criteria
Qualifiers
Age > 18 years
histologically proven low-grade glioma
indication for definitive or adjuvant radiotherapy
ability to understand character and personal consequences of the clinical trial
Disqualifiers
previous cerebral irradiation
contraindication for contrast-enhanced MRI
neurofibromatosis
participation in another clinical trial with competing objectives
Trial design
Treatments tested in this trial
- model-guided optimization of treatment plan
- standard treatment plan, no optimization